Therapeutic aspects of brain tissue pO2 monitoring after XXXX .

@entity1 @entity101 @entity510 @entity519 @entity1188 @entity2553 @entity385
Prolonged phases of brain tissue @entity519 (ptiO2 < 10 mmHg) lead to @entity385 . Therefore, the present study investigates the role of ptiO2--monitoring to guide hypervolemic @entity101 therapy in @entity1 suffering from severe @entity510 ( @entity510 ). Besides transcranial doppler, neuromonitoring of ICP/CPP was supplemented by ptiO2 monitoring. The ptiO2 catheter was inserted into viable tissue in the vascular territory with the highest risk for @entity2553 . @entity1 were divided in an @entity1188 (n = 21) and a non- @entity1188 group (n = 11). Critical CPP (< 70 mmHg) as well as @entity519 ptiO2 (< 10 mmHg) was significantly more frequent in the @entity1188 group (CPP: 25 vs 13%, p < 0.001; ptiO2: 16 vs 7%, p < 0.001). In both groups, over 25% of the critical ptiO2 values occurred at a CPP > 90 mmHg. In the @entity1188 group, 13 @entity1 showed transient phases of @entity519 which normalized under induced hypervolemic @entity101 and 5 @entity1 developed persistent @entity519 . In the non- @entity1188 group 6 @entity1 showed transient @entity519 and in 5 @entity1 no @entity519 values could be found. In conclusion, monitoring of ptiO2 provides an additional independent parameter to detect @entity519 events and to guide therapy.
